Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: An open-label, randomized controlled trial

Journal of Clinical Psychiatry

Volumn 73, Issue 5, 2012, Pages 669-675

  Covell, Nancy H ^a,b   McEvoy, Joseph P ^c,d   Schooler, Nina R ^e   Stroup, T Scott ^a,b   Jackson, Carlos T ^a,b   Rojas, Ingrid A ^a   Essock, Susan M ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Central Regional Hospital   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; PROLACTIN; RISPERIDONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84861831352     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07074     Document Type: Article

References (20)

1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93. doi:10.1093/schbul/sbp16 PubMed
2. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125-1132. doi:10.176/api.ajp.160.6. 125 PubMed (Pubitemid 41070972)
3. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117. doi:10.1016/j.euroneuro.204.07.03 PubMed (Pubitemid 39574406)
4. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007;191(2):131-139. doi:10.192/bjp.bp.105.017020 PubMed (Pubitemid 47204533)
5. Lindenmayer JP, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2007;17(2):138-144. doi:10.1016/j.euroneuro.206.08.04 PubMed (Pubitemid 44779189)
6. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-2377. doi:10.1038/np.2010.1 PubMed
7. Rosenheck RA, Krystal JH, Lew R, et al; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851. doi:10.1056/NEJMoa105987 PubMed
8. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19(4):241-249. doi:10.1097/01.yic.01350.92025.20 PubMed (Pubitemid 38901653)
9. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P Version 2.0). New York, NY: Biometrics Research Department, New York Psychiatric Institute; 1995.
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
11. Schooler NR. Evaluation of drug-related movement disorders in the aged. Psychopharmacol Bull. 1988;24(4):603-607. PubMed (Pubitemid 19054364)
12. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. doi:10.1/j.160-047.1970.tb0206. x PubMed
13. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40. doi:10.1080/0926230278623 PubMed (Pubitemid 30046590)
14. Weiden PJ, Miller AL. Which side effects really matter? screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001;7(1):41-47. doi:10.1097/0131746-201010-05 PubMed
15. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486-487. PubMed (Pubitemid 12152819)
16. Lieberman JA, Stroup TS, McEvoy JP, et al Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed (Pubitemid 41345943)
17. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090-2095. doi:10.176/api.ajp.163.12.2090 PubMed (Pubitemid 46114228)
18. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546. doi:10.408/JCP.v58n1205 PubMed (Pubitemid 28100274)
19. Essock SM, Schooler NR, Stroup TS, et al Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702-708. doi:10.176/api.ajp.201.1060908 PubMed
20. Citrome L, Jaffe A, Levine J. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Schizophr Res. 2010; 119(1-3):153-159. doi:10.1016/j.schres.2010.02.106 PubMed